News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
CSPC Pharmaceutical Group (01093.HK) SYH2095 Tablet Approved by US FDA to Commence Clinical Trials
CSPC Pharmaceutical Group (01093.HK) announced that the Groups Class 1 chemical innovative drug SYH2095 Tablet, jointly developed in collaboration with Hangzhou InnoStar Pharma Te...
Reset
Send
The window will close in 5 seconds
CSPC Pharmaceutical Group (01093.HK) SYH2095 Tablet Approved by US FDA to Commence Clinical Trials
Close
Recommend
6
Positive
10
Negative
4
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

CSPC Pharmaceutical Group (01093.HK)  +0.350 (+4.768%)    Short selling $185.59M; Ratio 24.126%   announced that the Groups Class 1 chemical innovative drug SYH2095 Tablet, jointly developed in collaboration with Hangzhou InnoStar Pharma Tech, has been approved by the US Food and Drug Administration (FDA) to commence clinical trials in the United States. SYH2095 Tablet is a novel highly selective lysine acetyltransferase 6 (KAT6) inhibitor and belongs to a class of epigenetic anti-cancer therapies. (de/d)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-22 16:25.)

Related News UBS Upgrades CSPC PHARMA (01093.HK) to Buy, Says Valuation Yet to Reflect AI Drug R&D Strength

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.